Neoprobe Corporation Awarded Grant from Qualifying Therapeutic Discovery Project Program

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has been awarded a grant of $244,479 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. The Company’s grant is related to the application submitted for its Lymphoseek® project.